FDA Approves Aprepitant Injection for CINV

February 28, 2019 – The FDA has expanded the approval of aprepitant injectable emulsion to include a 2-minute intravenous (IV) use for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). The decision is based on results of a two-part, phase I study that demonstrated bioequivalence and a similar safety profile for patients who received aprepitant as a standard 30-minute IV infusion compared with a 2-minute IV injection, which … (leggi tutto)